statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (Taiho) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code...

Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences

Latest Ratings for RCUS
 DateFirmActionFromTo Nov 2021CitigroupMaintainsBuy Nov 2021BarclaysMaintainsOverweight Nov 2021SVB LeerinkMaintainsOutperform
 View More Analyst Ratings for RCUS...

Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

In a report released on July 5, Peter Lawson from Barclays maintained a Buy rating on Arcus Biosciences (RCUS Research Report), with a price targ...

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a...

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Volume	433,942.00
52-Wk High	$25.47
52-Wk Low	$12.95

RCUS Arcus Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals